Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer (Q39828582)

15 September 2017

Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer (English)

1 reference

15 September 2017

Elizabeth McMillen

1

1 reference

15 September 2017

Fei Ye

2

1 reference

15 September 2017

Guanghu Li

3

1 reference

15 September 2017

Yong Wu

4

1 reference

15 September 2017

Guanghao Yin

5

1 reference

15 September 2017

Wei Liu

6

1 reference

15 September 2017

1 November 2010

1 reference

Experimental Lung Research

15 September 2017

1 reference

15 September 2017

36

1 reference

15 September 2017

9

1 reference

15 September 2017

531-537

1 reference

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

15 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F01902148.2010.482176

10.3109/01902148.2010.482176

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference